1169768-30-2

Basic information

• Product Name: Linolenic acid ketone
• Synonyms: (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-one; heptatriaconta-6,9,28,31-tetraen-19-one; dilinoleyl ketone
• CAS NO: 1169768-30-2
• Molecular Formula: C₃₇H₆₆O
• Molecular Weight: 526.91900
• Mol File: 1169768-30-2.mol

Chemical Properties

• CAS DataBase Reference: Linolenic acid ketone(CAS DataBase Reference)
• NIST Chemistry Reference: Linolenic acid ketone(1169768-30-2)
• EPA Substance Registry System: Linolenic acid ketone(1169768-30-2)

Safety Data

• Hazardous Substances Data: 1169768-30-2(Hazardous Substances Data)

Upstream product

• 4102-60-7 18-bromo-octadeca-6,9-diene 
• 60-33-3 linoleic acid 
• 4102-60-7 (Z,Z)-octadeca-9,12-dienyl bromide 
• 506-43-4 Linoleyl alcohol 
• 1169768-27-7 (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl formate 
• 51154-39-3 (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate 
• 1169768-28-8 (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-ol 

Downstream Products

• 1190197-97-7 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane 

Relevant articles and documents

Synthesis method of DLin-MC3-DMA intermediate

The invention provides a synthesis method of a DLin-MC3-DMA intermediate, the DLin-MC3-DMA intermediate is (6Z, 9Z, 28Z, 31Z)-triheptane-6, 9, 28, 31-tetraen-19-alcohol, and the synthesis method comprises the following steps: S1, carrying out substitution reaction on (6Z, 9Z)-18-bromooctadecane-6, 9-diene and nitromethane to obtain (6Z, 9Z, 28Z, 31Z), step S2, carrying out hydrolysis reaction on (6Z, 9Z, 28Z, 31Z)-19-nitrotriheptane-6, 9, 28, 31-tetraene to obtain (6Z, 9Z, 28Z, 31Z)-triheptane 6, 9, 28, 31-tetraen-19-ketone, and S3, the (6Z, 9Z, 28Z, 31Z)-triheptane-6, 9, 28, 31-tetraen-19-oneand a reducing agent are subjected to a reduction reaction, (6Z, 9Z, 28Z, 31Z)-triheptan-6, 9, 28, 31-tetraen-19-alcohol is obtained, and the reducing agent comprises sodium borohydride, potassium borohydride, lithium aluminum hydride or a mixture of sodium borohydride, potassium borohydride and lithium aluminum hydride. The synthesis method disclosed by the invention has the characteristics of simple process conditions, simplicity and convenience in operation, short route, high repeatability, higher total yield and contribution to industrial production.

The lipid membrane structure (by machine translation)

PROBLEM TO BE SOLVED: siRNA of Hepatocytic nucleic acid or the like can be efficiently deliver glycolipid film structure of the carrier. SOLUTION: eq. (I) (R the eq. (A) or eq. (B) a group represented by (n is 2 from 4 integer, m is an integer of from 2 5)) as a compound represented by structure including glycolipid glycolipid film. Selected drawing: no (by machine translation)

IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY

The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components

The invention relates to compositions and methods for site-specific delivery of nucleic acids by combining them with targeting ligands and endosomolytic components.

Lipids and compositions for the delivery of therapeutics

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alky lhetro cycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).

IONIZABLE CATIONIC LIPIDS

Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynu

COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B

The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES

Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\ the cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound that enhances uptake of the lipid particles b\ the cell The methods and compositions are useful in delivering a therapeutic agent to a cell, e g for the treatment of a disease or disorder in a subject

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo

Special (lipid) delivery: The role of the ionizable lipid pKa in the in?vivo delivery of siRNA by lipid nanoparticles has been studied with a large number of head group modifications to the lipids. A tight correlation between the lipid pKa?value and silencing of the mouse FVII gene (FVII ED50) was found, with an optimal pKa range of 6.2-6.5 (see graph). The most potent cationic lipid from this study has ED50 levels around 0.005?mg?kg?1 in mice and less than 0.03?mg?kg?1 in non-human primates.